Belatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. It is approved for the treatment of rheumatoid arthritis. Belatacept selectively blocks the process of T-cell activation. It was developed by Bristol-Myers-Squibb. Belatacept is only 2 amino acids different from abatacept (Orencia). FDA approved on June 15, 2011.
For prophylaxis of organ rejection. It is also used concomitantly with basiliximumab for induction therapy, mycophenolate, and corticosteriods in kidney transplant recepients that are seropositive for the Epstein-Barr virus.
Cedars Sinai Heart Institute/ Cedars Sinai Medical (Site # 71146), Los Angeles, California, United States
Tampa General Hospital (Site # 71150), Tampa, Florida, United States
NYU Langone Health (Site # 71177), New York, New York, United States
University of Alabama at Birmingham (Site # 71038), Birmingham, Alabama, United States
Children's Hospital of Los Angeles (Site #: 71036), Los Angeles, California, United States
Cedars-Sinai Medical Center (Site #: 71026), Los Angeles, California, United States
Local Institution - 0059, Genova, Liguria, Italy
Local Institution - 0042, Birmingham, Alabama, United States
Local Institution - 0041, Los Angeles, California, United States
Cleveland Clinic Foundation: Transplantation, Cleveland, Ohio, United States
University of California San Francisco School of Medicine: Transplantation, San Francisco, California, United States
University of Alabama School of Medicine: Transplantation, Birmingham, Alabama, United States
Duke University Health System, Durham, North Carolina, United States
Henri Mondor Hospital, Creteil, France
University of California, San Francisco, San Francisco, California, United States
Emory University, Atlanta, Georgia, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.